Literature DB >> 1960491

An investigation into the role of inflammatory cells in Dupuytren's disease.

J G Andrew1, S M Andrew, A Ash, B Turner.   

Abstract

An immunohistochemical study was performed on nodules excised from the palmar fascia of patients with Dupuytren's contracture. In cellular nodules, antibodies to actin (used as a marker for myofibroblasts), desmin, vimentin, Mac 387 (a macrophage marker) and leucocyte common antigen were used. A correlation was demonstrated between the numbers of macrophages and the presence of myofibroblasts. The presence of myofibroblasts is generally considered to indicate the active stage of the disease. Inflammatory cells other than macrophages were largely absent from the nodules, although lymphocytes were frequent in the tissue around the nodules. Microvascular changes were prominent in the nodules and pericyte proliferation was observed around occluded capillaries. Release of growth factors from macrophages may be important in Dupuytren's contracture, as is the case in other fibrotic diseases. The possible role of macrophages in the aetiology of Dupuytren's disease is discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1960491     DOI: 10.1016/0266-7681(91)90051-o

Source DB:  PubMed          Journal:  J Hand Surg Br        ISSN: 0266-7681


  11 in total

1.  Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target.

Authors:  Liaquat S Verjee; Jennifer S N Verhoekx; James K K Chan; Thomas Krausgruber; Vicky Nicolaidou; David Izadi; Dominique Davidson; Marc Feldmann; Kim S Midwood; Jagdeep Nanchahal
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

2.  Abnormal growth factor and cytokine expression in Dupuytren's contracture.

Authors:  K S Baird; J F Crossan; S H Ralston
Journal:  J Clin Pathol       Date:  1993-05       Impact factor: 3.411

Review 3.  Scientific understanding and clinical management of Dupuytren disease.

Authors:  Barbara Shih; Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

4.  Morphological and immunochemical differences between keloid and hypertrophic scar.

Authors:  H P Ehrlich; A Desmoulière; R F Diegelmann; I K Cohen; C C Compton; W L Garner; Y Kapanci; G Gabbiani
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

Review 5.  Dupuytren's: a systems biology disease.

Authors:  Samrina Rehman; Royston Goodacre; Philip J Day; Ardeshir Bayat; Hans V Westerhoff
Journal:  Arthritis Res Ther       Date:  2011-09-12       Impact factor: 5.156

Review 6.  Recent advances in the understanding of Dupuytren's disease.

Authors:  Thomas Layton; Jagdeep Nanchahal
Journal:  F1000Res       Date:  2019-02-28

Review 7.  The Role of IL-6 in Skin Fibrosis and Cutaneous Wound Healing.

Authors:  Blair Z Johnson; Andrew W Stevenson; Cecilia M Prêle; Mark W Fear; Fiona M Wood
Journal:  Biomedicines       Date:  2020-04-30

Review 8.  Connective Tissue Degeneration: Mechanisms of Palmar Fascia Degeneration (Dupuytren's Disease).

Authors:  S Karkampouna; M Kreulen; M C Obdeijn; P Kloen; A L Dorjée; F Rivellese; A Chojnowski; I Clark; Marianna Kruithof-de Julio
Journal:  Curr Mol Biol Rep       Date:  2016-07-14

Review 9.  Basics of Radiation Biology When Treating Hyperproliferative Benign Diseases.

Authors:  Franz Rödel; Claudia Fournier; Julia Wiedemann; Felicitas Merz; Udo S Gaipl; Benjamin Frey; Ludwig Keilholz; M Heinrich Seegenschmiedt; Claus Rödel; Stephanie Hehlgans
Journal:  Front Immunol       Date:  2017-05-03       Impact factor: 7.561

10.  Attenuation of Dupuytren's fibrosis via targeting of the STAT1 modulated IL-13Rα1 response.

Authors:  Moeed Akbar; Emma Garcia-Melchor; Sabarinadh Chilaka; Kevin J Little; Shatakshi Sood; James H Reilly; Foo Y Liew; Iain B McInnes; Neal L Millar
Journal:  Sci Adv       Date:  2020-07-10       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.